牛牛AI助理已提取核心訊息
bluebird bio, Inc., a biotechnology company, has announced the signing of a second outcomes-based agreement for its recently FDA-approved drug LYFGENIA. This agreement expands the coverage of LYFGENIA to approximately 200 million lives. LYFGENIA, which received FDA approval on December 8, 2023, is designed to treat sickle cell disease in patients aged 12 and older with a history of vaso-occlusive events. The company plans to provide additional updates on the commercial launch of LYFGENIA at the upcoming 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. This information was disclosed in a Form 8-K report filed with the Securities and Exchange Commission, which is not deemed filed for purposes of Section 18 of the Exchange Act nor incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, unless specifically referenced in such filings.
bluebird bio, Inc., a biotechnology company, has announced the signing of a second outcomes-based agreement for its recently FDA-approved drug LYFGENIA. This agreement expands the coverage of LYFGENIA to approximately 200 million lives. LYFGENIA, which received FDA approval on December 8, 2023, is designed to treat sickle cell disease in patients aged 12 and older with a history of vaso-occlusive events. The company plans to provide additional updates on the commercial launch of LYFGENIA at the upcoming 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. This information was disclosed in a Form 8-K report filed with the Securities and Exchange Commission, which is not deemed filed for purposes of Section 18 of the Exchange Act nor incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, unless specifically referenced in such filings.
生物技術公司bluebird bio, Inc. 宣佈爲其最近獲得美國食品藥品管理局批准的藥物LYFGENIA簽署第二份基於結果的協議。該協議將LYFGENIA的覆蓋範圍擴大到約2億條生命。LYFGENIA於2023年12月8日獲得美國食品藥品管理局的批准，旨在治療有血管閉塞事件史的12歲及以上患者的鐮狀細胞病。該公司計劃在即將於2024年1月9日舉行的第42屆摩根大通醫療年度會議上提供有關LYFGENIA商業發佈的更多最新信息。這些信息是在向美國證券交易委員會提交的8-K表報告中披露的，除非此類文件中特別提及，否則根據《交易法》第18條，該報告不被視爲已提交，也未以引用方式納入根據1933年《證券法》或《交易法》提交的任何文件中。
生物技術公司bluebird bio, Inc. 宣佈爲其最近獲得美國食品藥品管理局批准的藥物LYFGENIA簽署第二份基於結果的協議。該協議將LYFGENIA的覆蓋範圍擴大到約2億條生命。LYFGENIA於2023年12月8日獲得美國食品藥品管理局的批准，旨在治療有血管閉塞事件史的12歲及以上患者的鐮狀細胞病。該公司計劃在即將於2024年1月9日舉行的第42屆摩根大通醫療年度會議上提供有關LYFGENIA商業發佈的更多最新信息。這些信息是在向美國證券交易委員會提交的8-K表報告中披露的，除非此類文件中特別提及，否則根據《交易法》第18條，該報告不被視爲已提交，也未以引用方式納入根據1933年《證券法》或《交易法》提交的任何文件中。
有用
沒用